Treatments targeting MDS genetics: a fool's errand?

Research output: Contribution to journalReview article

Abstract

The myelodysplastic syndromes are collectively the most common myeloid neoplasms. Clonal hematopoiesis present in these diseases results in bone marrow failure characteristically seen in patients. The heterogeneity of myelodysplastic syndrome pathobiology has historically posed a challenge to the development of newer therapies. Recent advances in molecular characterization of myelodysplastic syndromes are improving diagnostic accuracy, providing insights into pathogenesis, and refining therapeutic options for patients. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.

Original languageEnglish (US)
Pages (from-to)277-285
Number of pages9
JournalHematology. American Society of Hematology. Education Program
Volume2018
Issue number1
DOIs
StatePublished - Nov 30 2018

Fingerprint

Myelodysplastic Syndromes
Hematopoiesis
Therapeutics
Bone Marrow
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Treatments targeting MDS genetics : a fool's errand? / Dezern, Amy.

In: Hematology. American Society of Hematology. Education Program, Vol. 2018, No. 1, 30.11.2018, p. 277-285.

Research output: Contribution to journalReview article

@article{ea62b7fde06b40f79e517e5ef4d7d85a,
title = "Treatments targeting MDS genetics: a fool's errand?",
abstract = "The myelodysplastic syndromes are collectively the most common myeloid neoplasms. Clonal hematopoiesis present in these diseases results in bone marrow failure characteristically seen in patients. The heterogeneity of myelodysplastic syndrome pathobiology has historically posed a challenge to the development of newer therapies. Recent advances in molecular characterization of myelodysplastic syndromes are improving diagnostic accuracy, providing insights into pathogenesis, and refining therapeutic options for patients. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.",
author = "Amy Dezern",
year = "2018",
month = "11",
day = "30",
doi = "10.1182/asheducation-2018.1.277",
language = "English (US)",
volume = "2018",
pages = "277--285",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Treatments targeting MDS genetics

T2 - a fool's errand?

AU - Dezern, Amy

PY - 2018/11/30

Y1 - 2018/11/30

N2 - The myelodysplastic syndromes are collectively the most common myeloid neoplasms. Clonal hematopoiesis present in these diseases results in bone marrow failure characteristically seen in patients. The heterogeneity of myelodysplastic syndrome pathobiology has historically posed a challenge to the development of newer therapies. Recent advances in molecular characterization of myelodysplastic syndromes are improving diagnostic accuracy, providing insights into pathogenesis, and refining therapeutic options for patients. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.

AB - The myelodysplastic syndromes are collectively the most common myeloid neoplasms. Clonal hematopoiesis present in these diseases results in bone marrow failure characteristically seen in patients. The heterogeneity of myelodysplastic syndrome pathobiology has historically posed a challenge to the development of newer therapies. Recent advances in molecular characterization of myelodysplastic syndromes are improving diagnostic accuracy, providing insights into pathogenesis, and refining therapeutic options for patients. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.

UR - http://www.scopus.com/inward/record.url?scp=85058755994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058755994&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2018.1.277

DO - 10.1182/asheducation-2018.1.277

M3 - Review article

C2 - 30504322

AN - SCOPUS:85058755994

VL - 2018

SP - 277

EP - 285

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

IS - 1

ER -